Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir
|
|
- Noah Horn
- 5 years ago
- Views:
Transcription
1 Alimentary Pharmacology and Therapeutics Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir B. Maasoumy*, B. Cobb, B. Bremer*, K. Luk, P. Halfon, S. Aslam, M. P. Manns*, M. Cornberg* & H. Wedemeyer* *Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. Roche Molecular Systems, Pleasanton, CA, USA. Laboratoire ALPHABIO, Hopital Ambroise Pare, Marseille, France. Correspondence to: Prof. Dr H. Wedemeyer, Carl-Neuberg Strasse 1, Hannover, Germany. Publication data Submitted 14 August 2013 First decision 12 September 2013 Resubmitted 3 October 2013 Accepted 12 October 2013 EV Pub Online 10 November 2013 SUMMARY Background Early on-treatment virological response is one of the most important predictors for sustained virological response (SVR) to treatment of chronic hepatitis C virus (HCV) genotype 1 infection with triple therapy including HCV protease inhibitors (PI). Treatment duration (24 vs. 48 weeks) is based on HCV RNA results at weeks 4 and 12 of PI therapy when HCV RNA must be undetectable to allow shorter therapy. Aim To analyse the reliability of HCV RNA measurements at key decision time points (weeks 4 and 12) and the predictive value of concordant or discordant assay results for SVR. Methods Weeks 4 and 12 samples of patients receiving telaprevir-containing triple therapy were initially tested with the AmpliPrep/COBAS-TaqMan_HCV-Test-v1.0 (limit of detection; LOD = 15IU/mL) and retested with the AmpliPrep/CO- BAS-TaqMan_HCV-Test-v2.0 (LOD = 15IU/mL) and the High_Pure/COBAS- TaqMan_HCV-Test-v2.0 (LOD = 20IU/mL). Results Concordance among the three test results in classifying samples as HCV RNA undetectable or detectable was only 55% at week 4, but 85% at week 12. Retesting of undetectable week 4 samples with the respective other assays revealed positive HCV RNA results in 32 50%. In 30%, HCV RNA was undetectable by all three tests at week 4 and all of these patients achieved SVR. In contrast, treatment failure occurred in 62% of patients with at least one detectable result, including cases with one or two other undetectable tests at week 4. Conclusions A single undetectable HCV RNA result at week 4 is not always associated with achieving SVR. Repeated testing in difficult-to-treat patients may identify those at risk for treatment failure. Aliment Pharmacol Ther 2014; 39: doi: /apt.12544
2 B. Maasoumy et al. INTRODUCTION Hepatitis C virus (HCV) infection is an important cause for liver cirrhosis and hepatocellular carcinoma. 1, 2 About 150 million people worldwide have persistent HCV infection. 3 Significant improvements have been achieved in treating hepatitis C with the development of direct-acting anti-virals (DAAs). 4, 5 First-generation DAAs, the protease inhibitors (PIs), telaprevir (TVR) and boceprevir (BOC), were approved for treatment of chronic HCV genotype 1 infection in Combination therapy containing one of these PIs, pegylated interferon alpha (Peg-IFN) and ribavirin (RBV) (triple therapy) is now the new standard of care for treatment of chronic HCV genotype 1 infection in many countries. 6 Treatment duration, as well as stopping criteria of PI-containing triple therapy, strongly depends on the virological response during treatment, determined by measurements of on-treatment HCV RNA levels. Accurate measurement of HCV RNA during therapy has become extremely relevant, in particular, the differentiation between undetectable HCV RNA (target not detected; TND) and HCV RNA detectable/not quantifiable (below the lower limit of quantification; BLOQ). The opportunity to shorten treatment duration from 48 to 24/28 weeks in noncirrhotic treatment-na ıve or relapse patients is one of the most important advantages of triple therapy. However, patients are only eligible for a shorter therapy if HCV RNA is undetectable at weeks 4 and 12 of TVR and weeks 8 and 12 of BOC-including regimens. All patients with any detectable HCV RNA, even those with levels BLOQ, require a full treatment course of 48 weeks, potentially leading to additional adverse effects and costs. 6, 7 Recent subanalyses of the pivotal trials of BOC and TVR demonstrated that the predictive value for achieving SVR is greater for a TND result in contrast to an HCV RNA level BLOQ at week 4 of PI therapy. 8 However, despite this enormous impact of detectable borderline viraemia, there are many uncertainties concerning the interpretations of HCV RNA measurements. There is no strict cut-off until HCV RNA levels are reported as detectable. The so-called limit of detection (LOD) is defined as the lowest HCV RNA level that is still detected by the assay in >95% of the cases. However, this does not necessarily mean that an HCV RNA level <LOD is reported as undetectable. Samples may also produce detectable results at even lower HCV RNA levels than the defined LOD, just with a lower likelihood, which, if detected, will be reported as detectable/bloq. Furthermore, it is, so far, not well studied whether different assays that are used for HCV RNA measurements have an impact on the HCV RNA result. The COBAS TaqMan HCV Test for Use with the High Pure System, v2.0 () has been used in most clinical trials. However, several other assays are available for HCV RNA monitoring (Table 1), which may differ in their ability to detect borderline levels of HCV RNA. As a result, on-treatment decisions may not exclusively depend on the virological response, but may be influenced by the assay that is used or sometimes even simply on chance considering, i.e. samples with HCV RNA levels below the LOD. In this study, plasma samples of 41 patients drawn 4 and 12 weeks after triple therapy with telaprevir, which were initially assessed with the COBAS AmpliPrep/CO- BAS TaqMan HCV Test, v1.0 (), were retested with two other HCV RNA assays, the COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 ( Table 1 CE-IVD HCV RNA viral load test analytical performance characteristics CE-IVD HCV test Viral load range (IU/mL) BLOQ reported result cut-off* Genotype 1 LOD (IU/mL) High pure TaqMan HCV Test, v <25 IU/mL, HCV RNA detected 20 CAP-TaqMan HCV Test, v <43 IU/mL, HCV RNA detected 15 CAP-TaqMan HCV Test, v <15 IU/mL, HCV RNA detected 15 Abbott RealTime HCV Test <12 IU/mL, HCV RNA detected 12 VERSANT HCV RNA 3.0 Assay (bdna) <615 IU/mL, HCV RNA detected 1000 * BLOQ, below the lower limit of quantification; test detects HCV RNA, but cannot quantify it. Results below the lower LOQ or LOD are reported as reflected by the BLOQ cut-off. LOD, limit of detection (below this level, HCV RNA can still be detected by assay), LOD is defined as the point at which HCV RNA is detected at >95%. Overall, LOD is most conservative estimate across genotype and matrix (plasma and serum). Assay LOD at 1000 IU/mL (95% detection rate), LLOQ and range determined per package insert, 615 IU/mL is <95% detection rate. 86 Aliment Pharmacol Ther 2014; 39: 85-92
3 Repeated HCV RNA testing predicts SVR ) and the TAQMAN Test, v2.0 (). Reliability of HCV RNA measurements at week 4 and 12 and predictive value of concordant or discordant test results were analysed. PATIENTS AND METHODS Patients. A total of 41 patients with chronic hepatitis C treated with pegylated interferon alpha 2a (88%) or 2b (12%), ribavirin and telaprevir were included in this study. Baseline characteristics of the study cohort are shown in table 2. There was no preselection of patients, as all consecutive individuals were included where sufficient plasma volume was available. No formal sample size calculation was performed, as this was a pilot study without reliable estimations for concordance and discordance between the different assays. For this reason, no statistical comparisons in detection rates between the assays were performed. RNA viral load measurements. The COBAS AmpliPrep/ COBAS TaqMan HCV Test, v1.0 () was used as part of routine clinical testing. Leftover EDTA lavender-top plasma from baseline, week 4 and week 12 samples were retested with the COBAS TaqMan HCV Test for Use with the High Pure System, v2.0 ( ) and the COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 (). Results that were undetectable were reported target not detected (TND). Any detected results either below the lower limit of quantification (BLOQ) or below the limit of detection (BLOD) were reported <43 ( Table 2 Baseline characteristics of the study cohort Patients (n) 41 Age (mean s.d.) Previous antiviral treatment Treatment-na ıve 5 (12%) Treatment-experienced 36 (88%) HCV genotype 1a 8 (20%) 1b 33 (80%) IL28B genotype CC 5 (12%) Non-CC 34 (83%) n/a 2 (5%) Cirrhotics 17 (41%) Platelets (/nl; mean s.d.) Albumin (g/l; mean s.d.) n, number; s.d., standard deviation; n/a, not available. ), <15 () or <25 () respectively. Quantifiable results (>LOQ) were reported as absolute numbers. Analysis of the virological outcome. An undetectable HCV RNA result 12 weeks after end of anti-viral treatment (SVR12) was chosen as the primary virological end point. One of the 41 selected patients died at week 16 of treatment and was therefore excluded from analysis. In one patient, there was no week 4 sample available and, in another patient, there was no week 12 sample. As a result, for each time point (weeks 4 and 12), data from 39 patients were available. Ethical Statement. This study was performed according to principals of good clinical practice as well as the declaration of Helsinki and approved by the local ethic committee of Hannover Medical School. RESULTS Concordance in week 4 samples HCV RNA was undetectable (TND) in % and detectable/not quantifiable (BLOQ) in 25 45% of the samples in the three assays. The was the assay that classified the most samples as HCV RNA TND (65%) and the, the assay with the most BLOQ results (45%) (Figure 1a). In almost all patients with quantifiable HCV RNA, viral load was still <100 IU/mL in all three tests except for one single patient, who even met the recommended stopping criteria according to HCV RNA result in the. Overall concordance through all three test results in classifying week 4 samples to be HCV RNA TND, BLOQ or >LOQ was 45% (Figure 1b). Overall concordance in either not detecting or detecting any HCV RNA was 55% at week 4 (Figure 1c). Concordance in week 12 samples At week 12, the majority of samples were tested HCV RNA TND ranging from 82.5% () to 90% () (Figure 1d). Only one patient had quantifiable HCV RNA at this stage. Concordance in classifying samples as HCV RNA detectable or undetectable was higher compared with week 4 (85%) (Figure 1e). Reliability of TND and BLOQ results at week 4 At week four, in 31 of the 40 selected samples, HCV RNA was reported as undetectable (TND) in at least one of the three test results. Less than half (42%) of these Aliment Pharmacol Ther 2014; 39:
4 B. Maasoumy et al. (a) 2.5% 10% 25% 15% 47.5% 45% 52.5% 65% 37.5% TND BLOQ >LOQ N = 40; 1 n/a Detectable HCV RNA Undetectable vs. Detectable/BLOQ vs. >LOQ (b) Concordance Discordance 45% 55% N = 40 20% 20% 15% 45% 17.5% 17.5% 22.5% (c) Undetectable vs. Detectable Concordance Discordance 55% 45% 20% 12.5% 12.5% N = 40 55% 20% 12.5% 12.5% (d) 5% 12.5% 5% 10% 5% 5% (e) Undetectable vs. Detectable Concordance 85% 15% 2.5% Discordance 5% 7.5% 82.5% N = 40; 1 n/a TND 85% BLOQ >LOQ Detectable HCV RNA 90% 7.5% N = 40 85% 2.5% 5% Figure 1 Overall assay concordance of results in patients on triple therapy. Distribution of HCV RNA viral load results by category ( Undetectable : Target not detected = TND; Detectable : Either Detected/Below the limit of quantification = BLOQ or Detected/Quantifiable HCV RNA = >LOQ) with the three different assays at week 4 of triple therapy (a). Concordance among the three assays in classifying week 4 samples as either HCV RNA TND, BLOQ and >LOQ (b) or simply as HCV RNA Undetectable or Detectable (c). Distribution of HCV RNA viral load results by category ( Undetectable : TND; Detectable : Either BLOQ or >LOQ) with the three different assays at week 12 of triple therapy (d). Concordance among the three assays in classifying week 12 samples as HCV RNA Undetectable or Detectable (e). samples were concordantly classified as TND through all three measurements. The highest level of discordance was documented between the and (38%) (Figure 2a). Conclusively, there was high chance that in samples, although classified as TND by one method, HCV RNA was detectable at least once in the same sample if tested with the other two assays. Likelihood ranged between 32% for samples with a TND result in the and 50% for samples previously classified as TND by the (Figure 2a). Almost one of four samples (23%) with undetectable HCV RNA in the, the assay used in the pivotal trials, had detectable HCV RNA in both other measurements. Similarly, in 69% of the samples once classified as detectable, but BLOQ, HCV RNA was not detected by one of the other two methods (Figure 2b). Reliability of TND and BLOQ results at week 12 At week 12, HCV RNA was not detected at least with one method in 37 samples. In contrast to the week 4 88 Aliment Pharmacol Ther 2014; 39: 85-92
5 Repeated HCV RNA testing predicts SVR (a) TND in (n = 21) (n = 26) (N = 19) Any (n = 31) 35% 21% 16% Detectable in 19% 29% 38% 10% 38% 1 other assay 50% 58% both other assays 23% 32% 5% (b) BLOQ in (n = 18) (n = 10) (N = 15) Any (n = 26) 40% 50% TND in 22% 30% 1 assay 56% 17% 50% 20% 40% 60% 73% 27% 69% 2 assays (c) TND in (n = 33) (n = 34) (N = 36) Any (n = 37) 6% 11% BLOQ/Detectable in 3% 3% 8% 1 other assay 6% 0% 3% 9% 0% 14% 16% both other assays 6% (d) BLOQ in (n = 5) (n = 4) (N = 2) Any (n = 7) 25% 40% TND in 80% 80% 40% 75% 1 assay 75% 50% 50% 50% 86% 2 assays 25% 50% Figure 2 Reliability of TND and BLOQ results at weeks 4 and 12 of triple therapy. Probability to be HCV RNA detected, although TND in one test at week 4 (a) and 12 (c) of triple therapy; Probability of a TND result by any assay in patients with an HCV RNA detected/bloq result in one test at week 4 (b) or week 12 (d) of triple therapy. samples, TND results were mostly confirmed in all three tests at week 12 (84%), Samples with HCV RNA TND showed detectable results in one of the respective other two tests in only 6 14% (Figure 2c). There were only 7 week 12 samples with detectable/ not quantifiable HCV RNA (BLOQ). The far majority (86%) of these BLOQ results were not confirmed, but reported TND in at least one of the respective other two tests (Figure 2d). Predictive value of week 4 HCV RNA results for the virological outcome Week 4 HCV RNA result had a high positive predictive value for the virological outcome in the here-analysed patient cohort (Figure 3a). In 12 (32%) of the 38 HCV genotype 1-infected patients with available week 4 and 12 samples (excluding one patient who died during treatment), HCV RNA was concordantly TND at week 4 in all three tests (ctnd). All of these patients achieved SVR12. In contrast, in the 18 patients with at least one TND result, but which was not confirmed by the two other measurements (discordant TND: dtnd), there were a significant number of virological breakthroughs and relapses. Overall, SVR rate was not higher than 50% in the dtnd group (Figure 3b). Chance to achieve SVR increased with each additional TND test result in the same week 4 sample, starting at 33% (n = 3/9) in patients with only one TND result, to 67% (n = 6/9) if HCV RNA was undetectable in two of three tests and finally up to the 100% (n = 12/12) in the ctnd group. On the other side, in the remaining eight patients, in whom HCV RNA was concordantly detectable through all three tests (notnd), only a single patient achieved SVR (13%) (Figure 3b). Of note, all of these patients still had HCV RNA results of less than 100 IU/mL in all three measurements, below the recommended stopping criteria, and 50% (n = 4) were even concordantly tested BLOQ. Any quantifiable HCV RNA (>LOQ) at week 4 in any single test had a negative predictive value of 100% (n = 4). Patients achieving SVR despite at least one detectable HCV RNA test result at week 4 (dtnd or notnd patients) were more likely to be younger (median age 45.5 yrs vs. 55 years). Furthermore, both patients with a detectable HCV RNA result at week 4, but carrying the favourable IL28B CC genotype, also achieved SVR. In contrast, all four patients infected with HCV GT1a and without ctnd experienced a virological treatment fail- Aliment Pharmacol Ther 2014; 39:
6 B. Maasoumy et al. (a) Percentage (%) SVR12 according to week TND BLOQ >LOQ n = 17/20 19/25 15/18 5/18 3/10 7/15 0/0 0/3 0/5 (b) SVR12 according to week Percentage (%) ctnd dtnd notnd n = 12/12 9/18 1/8 (c) Treatment failure according to week 12 HCV RNA Percentage (%) All ctnd Any detectable n = 15/37 9/30 6/7 (d) On treatment virological breakthrough according to week 12 HCV RNA result Percentage (%) n = All ctnd Any detectable 8/37 3/30 5/7 Figure 3 Treatment outcome according to HCV RNA results at key decision time points. Treatment outcome (achieving SVR12) according to HCV RNA viral load result at week 4 across assays (a) and in results combined (ctnd: concordant TND = TND results in all three assays; dtnd: discordant TND = one or two assays reported a TND result; notnd: no TND result) (b). HCV RNA viral load results at week 12 and subsequent treatment failure (c) and on-treatment virological breakthrough (d). ure, although three of them had at least one HCV RNA TND result at week 4. Predictive value of week 12 HCV RNA measurement for virological outcome Overall, there were 30 patients with week 12 samples in which HCV RNA level was concordantly undetectable in all the three assays. Not achieving ctnd at week 12 had a negative predictive value of 86%. There were nine patients with at least one detectable HCV RNA test result at week 12, including two meeting the recommended stopping criteria. Only a single patient (14%) with one or more detectable HCV RNA test results at week 12 achieved SVR (Figure 3c), while the frequency of virological breakthrough was 71% (n = 5/7) in those with at least one BLOQ result compared to only 10% (3/ 30) in those with ctnd at week 12 (Figure 3d). DISCUSSION Reliability of HCV RNA testing at key decision time points of triple therapy is absolutely crucial for optimal patient management, in particular, in differentiating undetectable from detectable results, including HCV RNA levels below the assays limit of quantification (BLOQ). Week 4 represents the most important time point for HCV RNA testing as it determines treatment duration in patients treated according to response-guided therapy (RGT). Furthermore, week 4 testing has been identified as the most valuable on-treatment SVR predictor. Here, we show that reliability of undetectable HCV RNA test results at week 4 of PI treatment may be limited and that retesting of samples can increase the positive predictive value for achieving SVR. The relatively high discordance of assay results at week 4 observed in our study may at least partly be explained by the way different assays classify samples with borderline HCV RNA. Truly HCV RNA-negative samples are unlikely to be misclassified as HCV RNA detectable, as specificities of modern HCV RNA PCR assays are extremely high. 9, 10 However, an undetectable (target not detected; TND) result does not necessarily mean that HCV RNA is really absent. While samples with HCV RNA levels above the assay s so-called limit of detection (LOD) give an HCV RNA signal in more than 95% of test results, things are entirely different if HCV RNA is still present, but yields detectable levels 90 Aliment Pharmacol Ther 2014; 39: 85-92
7 Repeated HCV RNA testing predicts SVR below the assay s LOD. In these cases where the actual HCV RNA titre is below the LOD, the results will fluctuate between a target not detected and a detectable result. For example, for the test with a LOD of 15 IU/mL, it has been shown that the test can detect HCV RNA levels of 2.5 IU/mL in approximately 50%. 11 Thus, discordance of replicate results should be expected (even with the same assay) in samples with low levels of HCV RNA. As a result, it may simply depend on chance whether a sample is classified as detectable/bloq or TND. Therefore, the likelihood to detect HCV RNA below the LOD increases by additional testing. It needs to be discussed whether different performances of the assays used here may have contributed to the observed discordance. In this study, we used three different versions of the COBAS Taqman assays: the COBAS AmpliPrep/COBAS TaqMan HCV Test, v1.0 (), the COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 (), and the COBAS TaqMan HCV Test for Use with the High Pure System, v2.0 (). The is commonly used in drug trials, including the pivotal studies of TVR and BOC. In contrast, the and are widely used in routine HCV RNA testing. Analytical sensitivity of all three tests was recently compared and shown to have similar LODs (overlapping 95% confidence intervals). 12 In our study, the number of undetectable results was also comparable for all three assays. Thus, reliability of HCV RNA TND results at week 4 seems to be limited, no matter which assay is used. The second important finding of our study was that accuracy of SVR prediction can be improved by retesting of samples at key decision time points, in particular, at week 4. In a retrospective investigation of TVR and BOC phase 2 and 3 trials, an undetectable HCV RNA in contrast to a BLOQ week 4 result was an important SVR predictor. In the REALIZE study, patients with HCV RNA TND at week 4 had a 22% higher SVR rate than those with an HCV RNA BLOQ after TVR-containing triple therapy. Still, about one of five patients did not achieve a SVR despite a week 4 TND result determined by one testing. 8 Data of our study widely confirmed these findings as long as only one HCV RNA test was applied. Overall SVR rates were lower in our study, but a higher frequency of cirrhotics and/or previous nonresponders were included. However, the positive predictive value of an undetectable HCV RNA at week 4 still increased to 100% by retesting of samples, even in this difficult-to-treat cohort. In contrast, patients with virological failure despite a TND result at week 4 were all identified by additional testing. In addition to low viraemia at week 4 of therapy, other predictive factors for SVR may be considered to individualise therapy, in particular, if only one HCV RNA measurement is applied. In our study, positive SVR predictors were younger age and IL28B CC, while HCV genotype 1a was associated with treatment failure. However, value of such predictors under the circumstances of discordant TND and/or BLOQ week 4 HCV RNA results needs further prospective validation in larger cohorts. Our study has obvious limitations. We used three different assays for retesting of the samples, which may lead to a slight overestimation of discordance after repeated testing. On the other side, these also allowed demonstrating that no major differences occur among the three methods. Another limitation lies in the relatively small and heterogeneous study cohort as well as the retrospective study design. Therefore, data certainly need to be confirmed in larger, adequately powered and more homogenous cohorts in prospective studies before strict recommendations on treatment decisions and need for regular retesting can be established. Furthermore we here only compared three different versions of the Roche CTM assay. There are several other assays available and our data may not directly be transferred to these assays. Thus, future studies need to address the comparison of other assays and the significance of discordant results for the treatment outcome. However, findings presented here may still have important clinical implications to optimise management of PI-containing triple therapy. Recent studies in real-life cohorts demonstrated that safety and efficacy of Peg-IFN/RBV/PI triple therapy are limited in patients with liver cirrhosis. Serious adverse events of therapy, including severe infections and deaths, were reported in this specific patient cohort. 13, 14 In addition, SVR chances are also lower in cirrhotics, but, at the same time, these patients are in most urgent need for treatment. To avoid unnecessary side effects, it is therefore crucial to identify reliable SVR predictors. Here, confirming TND week 4 results may give important additional information to ensure a favourable risk/benefit ratio. Findings of this study results may also be relevant for patients considered as easy-to-treat. We here show that the decision for shortening of treatment is simply based on chance in a significant number of patients, as reliability of TND and BLOQ results is limited at week 4, the key decision time point of RGT. However, simple retesting in patients with otherwise beneficial response factors would most likely lead to overtreatment if all patients with discordant TND results would be treated for 48 weeks. Aliment Pharmacol Ther 2014; 39:
8 B. Maasoumy et al. Vermehren et al. presented preliminary data where, in a more easy-to-treat cohort, the majority of patients with a TND result in the, but a detectable HCV RNA result after retesting with the Abbott RealTime assay, still achieved SVR despite a shortening of treatment according to RGT criteria. 15 Thus, a more precise and reliable system is needed to define the optimal treatment duration. A possible approach would be to include several predictors in addition to RVR, such IL28B polymorphisms and HCV subgenotypes (1a vs. 1b). In conclusion, reliability of week 4 HCV RNA levels stated as TND or undetectable is limited if only a single HCV RNA measurement is performed. Patients likely to be truly HCV RNA-negative at week 4, defined by confirmed TND results, have a very high chance to achieve a SVR, even those with unfavourable baseline predictors. AUTHORSHIP Guarantor of the article: Benjamin Maasoumy. Author contributions: BM, BC, BB, SA and KL collected and analysed the data. BM, PH, MPM, MC and HW designed the research study. BM, MPM, MC and HW wrote the paper. All authors revised the manuscript critically. All authors approved the final version of the manuscript. ACKNOWLEDGEMENTS Declaration of personal interests: BM received lecture fees from Roche Diagnostics, Roche Pharma, Merck/MSD, travel support from Janssen-Cilaq and consulting fees from Abbott Molecular. BC, KL and SA are employees of Roche Diagnostics. BB has no conflict of interest. PH received consulting fees from Roche Diagnostics and lecture fees from Merck and Vertex. MPM received consulting fees from Roche, BMS, Gilead, Boehringer Ingelheim, Novartis, Tibotec, Vertex, GSK, Merck/MSD, grant/research support from Roche, BMS, Gilead, Boehringer Ingelheim, Novartis, Merck/MSD and lecture fees from Merck/MSD, Roche, BMS, Gilead. MC received lecture fees from Merck, Roche Pharma, Roche Diagnostics, Gilead, BMS, Novartis, consulting fees from Merck, Roche Pharma, Roche Diagnostics, Gilead, Novartis and grant support from Merck, Roche. HW received consulting fees from Transgene, MSD, Roche, Gilead, Abbott, BMS, Falk, grant/research support from MSD, Novartis, Gilead, Roche, Abbott and lecture fees form BMS, MSD, Novartis, ITF. Declaration of funding interests: This work was funded, in part, by the IFB-Tx a project of the BMBF (German Federal Ministry of Education and Research). Roche diagnostics provided the HCV RNA tests. REFERENCES 1. EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol 2011; 55: Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26: Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to hepatitis C virus seroprevalence. Hepatology 2012; 57: Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56(Suppl. 1): S Dusheiko G, Wedemeyer H. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon s long goodbye. Gut 2012; 61: Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: Sarrazin C, Berg T, Cornberg M, et al. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol 2012; 50: Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012; 55: Chevaliez S, Pawlotsky JM. How to use virological tools for optimal management of chronic hepatitis C. Liver Int 2009; 29(Suppl. 1): Chevaliez S, Pawlotsky JM. Virological techniques for the diagnosis and monitoring of hepatitis B and C. Ann Hepatol 2009; 8: Zitzer H, Heilek G, Truchon K, et al. Second-generation Cobas AmpliPrep/ Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dualprobe assay design. J Clin Microbiol 2013; 51: Wedemeyer H, Kessler HH, Michel- Treil V, et al. The ExPECT study: an international multicenter clinical trial evaluating low HCV RNA viremia with the COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 compared to assays used in routine clinical practise and in drug trials. Hepatology 2012; 56 (Suppl.): 676A 7A. 13. Maasoumy B, Port K, Markova AA, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS ONE 2013; 8: e Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with hcv-cirrhosis in a multicentre cohort of the french early access programme (anrs co20-cupic) nct J Hepatol 2013; 59: Vermehren J, Aghemo A, Pfeiffer KH, et al. Undetectable HCV-RNA in telaprevir-treated patients: low concordance between two highly sensitive real-time pcr assays. J Hepatol 2013; 58(Suppl.): Aliment Pharmacol Ther 2014; 39: 85-92
Optimal Treatment with Boceprevir. Michael Manns
Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013 Acknowledgements Benjamin Maasoumy Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationAccepted Manuscript. Letter to the Editor. Reply to: From the CUPIC study: Great times are not coming (?)
Accepted Manuscript Letter to the Editor Reply to: From the CUPIC study: Great times are not coming (?) Christophe Hezode, Helene Fontaine, Yoann Barthe, Fabrice Carrat, Jean-Pierre Bronowicki PII: S0-()00-
More informationPredictors for HCV treatment outcome: lower limit of quantification vs. limit of detection
Predictors for HCV treatment outcome: lower limit of quantification vs. limit of detection Department of Medical Microbiology MUMC+, Maastricht University b.conjaerts@student.maastrichtuniversity.nl Abstract
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationOriginal article HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals
Antiviral Therapy 2015; 20:177 183 (doi: 10.3851/IMP2810) Original article HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals Gavin Cloherty 1 *, Daniel
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationEvaluation of performances of VERSANT HCV RNA 1.0 assay (kpcr) and Roche COBAS AmpliPrep/COBAS TaqMan HCV test v2.0 at low level viremia
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Short Communication Evaluation of performances of VERSANT HCV RNA 1.0 assay (kpcr) and Roche COBAS AmpliPrep/COBAS TaqMan HCV
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationHCV Treatment in 2016: is there still a role for IFNa and ribavirin?
HCV Treatment in 2016: is there still a role for IFNa and ribavirin? Heiner Wedemeyer Hannover Medical School Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, AbbVie,
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationDigestive and Liver Disease
Digestive and Liver Disease 45S (2013) S323 S331 Contents lists available at ScienceDirect Digestive and Liver Disease journal homepage: www.elsevier.com/locate/dld Review article The importance of HCV
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationTreatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble
Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989
More informationCurrent Standards in the Treatment of Chronic Hepatitis C
REVIEW ARTICLE Current Standards in the Treatment of Chronic Hepatitis C Wolf Peter Hofmann, Christoph Sarrazin, Stefan Zeuzem SUMMARY Background: In Germany, 0 000 to 500 000 people are chronically infected
More informationCurrent Treatments for HCV
Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,
More informationMulticentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment
DOI 10.1007/s00430-015-0443-9 RAPID COMMUNICATION Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment F. Wiesmann 1 G. Naeth 1 A. Berger 2 H. H.
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More informationAntiviral Therapy 2014; 19: (doi: /IMP2723)
Antiviral Therapy 214; 19:449 454 (doi: 1.3851/IMP2723) Original article Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2. and the Abbott RealTime hepatitis C assays implications for
More informationHEPATITIS C VIRUS (HCV) GENOTYPE TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS - 027 Effective Date:
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationInterferon free therapy Are we getting there? Graham R Foster Queen Marys University of London
Interferon free therapy Are we getting there? Graham R Foster Queen Marys University of London IFN free therapy Disclosures I have received personal and institutional funding from companies that sell drug
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationManagement of HCV in Decompensated Liver Disease
Management of HCV in Decompensated Liver Disease Michael P. Manns Hannover Medical School (MHH) Department of Gastroenterology, Hepatology and Endocrinology Helmholtz Center for Infection Research (HZI),
More informationNew Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD
Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b
More informationFollow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France
9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures
More informationReview Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationUtility of Virological Assays at the DAA Era
Utility of Virological Assays at the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationStrategies towards cure of HCV infection: a personalized approach. Heiner Wedemeyer Hannover Medical School Hannover, Germany
Strategies towards cure of HCV infection: a personalized approach Heiner Wedemeyer Hannover Medical School Hannover, Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Biolex,
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationHepatitis C Virus Genotype 2 may not be detected by the Cobas AmpliPrep/Cobas. TaqMan HCV Test, version 1.0
JCM Accepts, published online ahead of print on 25 September 2013 J. Clin. Microbiol. doi:10.1128/jcm.02102-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Hepatitis C Virus
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationLes Inhibiteurs de Protéase du VHC
Les Inhibiteurs de Protéase du VHC Pr Jean-Michel Pawlotsky National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationChronic infection with hepatitis C virus (HCV)
VIRAL HEPATITIS Concordance of Sustained Virological Response 4, 12, and 24 Weeks Post-Treatment With Sofosbuvir- Containing Regimens for Hepatitis C Virus Eric M. Yoshida, 1 Mark S. Sulkowski, 2 Edward
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationHepatitis C 17 months experience with Sofosbuvir/Ledipasvir (Harvoni)
Hepatitis C 17 months experience with Sofosbuvir/Ledipasvir (Harvoni) Prof. Dr. Markus Cornberg Klinik für Gastroenterologie, Hepatologie und Endokrinologie Antalya, 13.05.2016 Markus Cornberg, Hannover
More informationHepatitis C - results in real life
Hepatitis C - results in real life Robert Flisiak Department of Infectious Diseases and Hepatology Medical University of Białystok, Poland 10th PHC Paris, 30-31 January 2017 Disclosures Advisor and/or
More informationHighlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases
Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other TELAPREVIR INCIVEK 37629 This drug requires a written request for prior authorization. All requests for hepatitis C medications require review by a pharmacist prior
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationComparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks
Comparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks C Sarrazin, 1 M Buti, 2 C Moreno, 3 M Gschwantler, 4 GR Foster,
More informationWilhelminenspital, Vienna, Austria; 5 Queen Mary Hospital, University of London, Barts Health, London, UK; 6
Shortening overall treatment to 12 weeks of simeprevir plus PR in treatment-naïve chronic hepatitis C genotype 1 patients: assessment of baseline and Week 2 on-treatment predictors of SVR T Asselah, 1
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationTreatment of chronic hepatitis C in drug-naïve patients
Treatment of chronic hepatitis C in drug-naïve patients 8th International Workshop on HIV & Hepatitis Co-infection Madrid, 31. May 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische
More informationOptimal ltherapy in non 1 genotypes:
Optimal ltherapy in non 1 genotypes: genotype 2 and 3 patients Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy craxanto@unipa.it Peg IFN alpha plus ribavirin : SVR rate of >80%
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationDAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France
DAA-based treatment in cirrhotic and post-transplanted patients Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France Cirrhosis and transplantation 2 populations with similar issues Hepatic impairment
More informationABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1
ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationPierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine
Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationEfficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience
Efficacy and safety of protease inhibitors for sever hepatitis C recurrence after liver transplantation: a first multicentric experience A. Coilly, B. Roche, J. Dumortier, D. Botta-Fridlund, V. Leroy,
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationPersonalised Treatment with Telaprevir in Graham R Foster Professor of Hepatology Queen Marys University of London
Personalised Treatment with Telaprevir in 2014 Graham R Foster Professor of Hepatology Queen Marys University of London Telaprevir in 2014 Disclaimers I have received funds from: BI, BMS, Janssen, Novarts,
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationDisclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR
29/9/214 Genetic determinants of ᴧ HCV treatment outcome Disclosures Advisory board member - Gilead, Abbvie, Bristol-Myers Squibb (BMS), Janssen, Merck, and oche Speaker - Gilead, Janssen, Merck, BMS,
More informationStick or twist management options in hepatitis C
Stick or twist management options in hepatitis C Dr. Chris Durojaiye & Dr. Matthijs Backx SpR Microbiology and Infectious Diseases University Hospital of Wales, Cardiff Patient history 63 year old female
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationMonitoring of HCV RNA. Hepatitis C Requirements of Antiviral Therapy Monitoring
Monitoring of HCV RNA Hepatitis C Requirements of Antiviral Therapy Monitoring Hepatitis C Requirements of Antiviral Therapy Monitoring Author: Ute Hofmann,, Konrad-Zuse-Str. 1, 07745 Jena, Germany Beatrix
More informationROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV
ROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV (Especially HCV-6) WK Seto Clinical Assistant Professor Department of Medicine Queen Mary Hospital The University of Hong Kong HCV GENOTYPES:
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationMichael Fried, MD University of North Carolina Chapel Hill, NC. Ira Jacobson, MD Weill Cornell Medical College New York, NY
Nezam Afdhal, MD Beth Israel Deaconess Medical Center Boston, MA Kim Brown, MD Henry Ford Hospital Detroit, MI Michael Fried, MD University of North Carolina Chapel Hill, NC Jordan Feld, MD Toronto Western
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 4
National Clinical Guidelines for the treatment of HCV in adults Version 4 November 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationHepatitis D. Challenges in 2018
Hepatitis D Challenges in 2018 Heiner Wedemeyer Essen University Hospital, Germany Germany Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, AbbVie, Abivax, BMS, Boehringer Ingelheim,
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationIdentifying Subgroups in Product Labeling: 2 Recent Case Studies. Martin King AbbVie
Identifying Subgroups in Product Labeling: 2 Recent Case Studies Martin King AbbVie Disclosures The presentation was sponsored by AbbVie. AbbVie contributed to the design, research, and interpretation
More informationDivision of Gastroenterology and Hepatology, Kawasaki Municipal Tama Hospital, Kawasaki, Japan 3
Turk J Gastroenterol 2016; 27: 165-72 Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy? LIVER Hiroki
More informationProgression of the disease. Heiner Wedemeyer
Progression of the disease Heiner Wedemeyer Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Abvie, Biolex, BMS, Boehringer Ingelheim, Eiger, Gilead, ITS, JJ/Janssen-Cilag, Medgenics,
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationQUANTITATIVE HEPATITIS C VIRUS (HCV) RNA
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HEPATITIS C VIRUS (HCV) RNA Policy Number: PDS - 028 Effective Date:
More informationTriple therapy with telaprevir or boceprevir: management of side effects
Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationOriginal article Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV
Antiviral Therapy 2016; 21:605 609 (doi: 10.3851/IMP3066) Original article Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV Edward J Gane 1,2 *, Robert H Hyland 3, Di An 3, Evguenia
More informationImproving Treatment Success Rates for HCV in a Managed Care Setting
Improving Treatment Success Rates for HCV in a Managed Care Setting Bruce R. Bacon, MD James F. King MD Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More information